Skip to main content

Table 2 Risk of bias assessment of studies included in the in the systematic review

From: Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review

Meta-data

Methodology

Newcastle-Ottawa Scale

Author

Publication Date

Origin

Study design*

Selection

Comparability

Exposure

Quality

Gómez Peña et al [15]

2015

Spain

+−

****

*

***

8

Beauclair et al [16]

2007

France

+−

****

*

***

8

Lemieux et al [17]

2013

Canada

–

****

**

***

9

Roca L et al [2]

2013

France

++

****

*

***

8

Tan et al [18]

2020

China

+−

****

*

***

8

Peddi et al [19]

2022

United States

−+

****

**

***

9

Stanton et al [20]

2015

United States

–

****

*

***

8

Boekhout et al [21]

2016

Korea

++

****

**

***

9

Serie et al [23]

2017

United States

−+

****

**

***

9

Udagawa et al [24]

2018

Japan

–

****

**

***

9

Nakano et al [25]

2019

Japan

–

****

**

***

9

Wang et al [26]

2019

United States

–

**

**

**

6

Zhang et al [27]

2020

China

+−

****

**

***

9

Feng et al [28]

2021

China

–

****

**

**

8

Mean Newcastle-Ottawa Scale score

8.3

  1. Abbreviations: NA Not Available, NR Not Reported; *Study design: Prospective (+), Retrospective (−); single centre (−), multicentre (+)
  2. Maximum quality score = 9; 0–7 points were considered lower quality, and 8–9 points were considered as higher quality